Senolytic Drug Classes Compared: Natural vs Synthetic vs Prescription

Expert Summary

Senolytic compounds fall into four mechanistic classes: (1) BCL-2 family inhibitors (natural: fisetin, quercetin; synthetic: navitoclax, venetoclax), (2) Kinase inhibitors (dasatinib — src/ABL/EPHA2), (3) ROS-mediated (piperlongumine, EGCG), and (4) Protein-protein interaction disruptors (FOXO4-DRI peptide). Each class offers different potency, cell type specificity, safety, and accessibility.

Key Facts

• BCL-2 inhibitors (natural — fisetin, quercetin): Potency: moderate. Safety: excellent. Access: OTC. Cell types: fat, brain, muscle senescent cells. Evidence: strong preclinical + emerging human. Best for: self-directed natural protocol.
• BCL-2 inhibitors (synthetic — navitoclax): Potency: very high. Safety: poor (thrombocytopenia). Access: research only. Evidence: strong preclinical. Best for: not currently clinical; research applications.
• Kinase inhibitors (dasatinib): Potency: high (complementing quercetin). Safety: moderate (requires monitoring). Access: prescription only. Evidence: strongest human evidence. Best for: physician-supervised aging protocols.
• ROS-mediated (piperlongumine, EGCG): Potency: mild-moderate. Safety: good. Access: research-grade (piperlongumine), OTC (EGCG). Evidence: moderate preclinical. Best for: EGCG as supplementary agent.
• Peptide (FOXO4-DRI): Potency: high. Safety: unknown in humans. Access: research only. Evidence: strong animal. Best for: future clinical development target.
• Selection guidance: Start with natural BCL-2 inhibitors (fisetin + quercetin). Consider prescription kinase inhibitor (dasatinib) under physician supervision from age 60+. Avoid pharmaceutical synthetic BCL-2 inhibitors (navitoclax) due to platelet risk.

Recommended Products

Frequently Asked Questions

When will synthetic senolytic drugs be available for aging?

Modified navitoclax variants (BCL-XL selective or platelet-sparing) are in early development. If Phase 1/2 trials succeed, a next-generation synthetic senolytic could reach Phase 3 within 5–7 years. FOXO4-DRI human trials have not yet begun.

Are natural senolytics "good enough" for most people?

For individuals under 60 with moderate senescent cell burden, natural senolytics (fisetin + quercetin monthly) likely provide most of the accessible benefit. Pharmaceutical senolytics offer additional potency particularly relevant for established disease and older individuals.

Scientific References

• Zhu Y et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015. PMID: 25754370
• Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. Journal of Internal Medicine. 2020. PMID: 32686219